Cerenome(NASDAQ) CNSY

Market Cap$21.40M

Since IPO (2003)-100%

5 Year-100%

1 Year-75%

1 Month-27%

$2.70

-4.26%

-0.12Today

Cerenome last closing stock price
Metric	Price	Date
Last close	USD 2.82	2026-08-31

Cerenome stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.73%	USD 2.96	2026-08-24
1 month	-27.13%	USD 3.87	2026-07-31
3 month	-48.45%	USD 5.47	2026-06-02
Year to date	-77.98%	USD 12.81	2025-12-31
1 year	-75.26%	USD 11.40	2025-08-29
3 year	-95.97%	USD 70.00	2023-09-01
5 year	-99.6%	USD 712.50	2021-09-01
Since inception	-100%	USD 10,404,949.38	2003-07-01

Cerenome Financials at a Glance

Market Cap

$21.40M

Revenue (TTM)

$4.20M

Net Income (TTM)

-$26.09M

EPS (TTM)

-$4.41

P/E Ratio

-0.64

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$2.70

Volume

64,262.473

Open

$2.79

Price

$2.70

Volume

64,262.473

Open

$2.79

Previous Close

$2.82

Daily Range

$2.62 - $2.80

52-Week Range

$2.62 - $23.43

Estimated Earnings Date

Oct 29, 2026

Dividend

$0.00

Beta (Volatility)

1.16 (Average)

Price

$2.70

Volume

64,262.473

Open

$2.79

Previous Close

$2.82

Daily Range

$2.62 - $2.80

52-Week Range

$2.62 - $23.43

Estimated Earnings Date

Oct 29, 2026

CNSY News

Plus Therapeutics Posts Q2 Profit Jump

Motley Fool Markets TeamAug 14, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cerenome

Plus Therapeutics, Inc. is a U.S.-based pharmaceutical company dedicated to developing targeted radiotherapeutics for central nervous system cancers. With innovative technologies, they focus on delivering radiation directly to tumors, aiming to reduce damage to healthy tissues. This approach could revolutionize treatment for rare and challenging cancer types.

Products and Services

Rhenium-186 obisbemeda: A radiotherapeutic designed for CNS cancers delivered directly to tumor sites.

Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere: Targeted treatment for solid organ cancers like liver cancer.

Research and development in radiotherapeutic technologies.

What Makes Plus Therapeutics, Inc. Special

Plus Therapeutics leverages its proprietary nanoliposome technology to deliver radiotherapeutic agents precisely, potentially improving efficacy and minimizing damage to healthy tissues. This sets them apart by addressing unmet needs in rare and difficult-to-treat cancer markets.

Five Things You Need to Know

Focus on treating rare cancers with significant unmet medical needs.

Leading product, Rhenium-186 obisbemeda, is in advanced clinical trials for various CNS cancers.

Strong strategic partnerships enhance supply chain and development capabilities.

Headquartered in Texas, near major cancer research institutions.

Uses a patented platform technology with potential applications beyond current cancer targets.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Marc H. Hedrick, MD, MBA

Website

www.plustherapeutics.com

Headquarters

Houston, TX 77021, US

CNSY Financials

Key Financial Metrics (TTM)

Gross Margin

89.58%

Operating Margin

-628.12%

Net Income Margin

-620.70%

Return on Equity

-394.17%

Return on Capital

-317.58%

Return on Assets

-185.94%

Earnings Yield

-1.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$21.40M

Shares Outstanding

7.59M

Volume

64.26K

Avg. Volume

137.91K

Financials (TTM)

Gross Profit

$3.77M

Operating Income

-$26.40M

EBITDA

-$22.39M

Operating Cash Flow

-$22.18M

Capital Expenditure

-$1.37M

Free Cash Flow

-$23.55M

Cash & ST Invst.

$8.59M

Total Debt

$44.00K

Cerenome Performance Analysis

Cerenome annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 224,000	N/A
2023	2023-12-31	USD 4,913,000	2093.3%
2024	2024-12-31	USD 5,824,000	18.5%
2025	2025-12-31	USD 5,213,000	-10.5%

Cerenome sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	0.5%
Q4	2025-12-31	-2.1%
Q1	2026-03-31	-24.8%
Q2	2026-06-30	-60.0%

Cerenome annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -289.59	-30.3%
2023	2023-12-31	USD -105.99	-63.4%
2024	2024-12-31	USD -58.52	-44.8%
2025	2025-12-31	USD -7.19	-87.7%

Cerenome sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	99.4%
Q4	2025-12-31	-5.0%
Q1	2026-03-31	N/A
Q2	2026-06-30	-26.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$411.00K

-70.4%

Gross Profit

$260.00K

-80.1%

Gross Margin

63.26%

N/A

Market Cap

$21.40M

N/A

Market Cap/Employee

$764.38K

N/A

Employees

N/A

Net Income

-$9.01M

-274.8%

EBITDA

-$8.91M

-268.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$8.59M

+24.8%

Total Debt

$44.00K

+46.7%

Accounts Receivable

$1.76M

+72.5%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$44.00K

+46.7%

Return on Assets

-1.86%

N/A

Return on Invested Capital

-4.83%

N/A

Free Cash Flow

-$7.63M

-31.5%

Operating Cash Flow

-$7.13M

-23.0%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.31-0.07%

NVDANvidia

NVDANvidia$217.71-0.01%

INTCIntel

INTCIntel$88.68-0.01%

NUNu Holdings

NUNu Holdings$14.48-0.01%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.38-0.02%

PCGPG&E

PCGPG&E$13.58+0.02%

NOKNokia

NOKNokia$9.91-0.02%

Questions About CNSY

What is the current price of Cerenome?

Cerenome is trading at $2.70 per share.

What is the 52-week range for Cerenome?

Over the past 52 weeks, Cerenome has traded between $2.62 and $23.43.

How much debt does Cerenome have?

As of the most recent reporting period, Cerenome reported total debt of $44.00K.

How much cash does Cerenome have on hand?

Cerenome reported $2.37M in cash and cash equivalents in its most recent financial results.

What is Cerenome’s dividend yield?

Cerenome does not currently have a dividend yield.

Cerenome(NASDAQ) CNSY

Cerenome Financials at a Glance

CNSY News

Plus Therapeutics Posts Q2 Profit Jump

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Cerenome

Products and Services

What Makes Plus Therapeutics, Inc. Special

Five Things You Need to Know

CNSY Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Cerenome Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About CNSY

What is the current price of Cerenome?

What is the 52-week range for Cerenome?

How much debt does Cerenome have?

How much cash does Cerenome have on hand?

What is Cerenome’s dividend yield?

Premium Investing Services